Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review

J Bicker, G Alves, A Fortuna, A Falcão - European Journal of Pharmaceutics …, 2014 - Elsevier
During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

Involvement of Astrocytes in the Formation, Maintenance, and Function of the Blood–Brain Barrier

G Schiera, CM Di Liegro, G Schirò, G Sorbello… - Cells, 2024 - mdpi.com
The blood–brain barrier (BBB) is a fundamental structure that protects the composition of the
brain by determining which ions, metabolites, and nutrients are allowed to enter the brain …

Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone

T Okura, A Hattori, Y Takano, T Sato… - Drug metabolism and …, 2008 - ASPET
The purpose of this study was to characterize blood-brain barrier (BBB) transport of
oxycodone, a cationic opioid agonist, via the pyrilamine transporter, a putative organic …

Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine

L Peura, K Malmioja, K Huttunen, J Leppänen… - Pharmaceutical …, 2013 - Springer
Purpose Drug delivery to the brain is impeded by the blood-brain barrier (BBB). Here, we
attempted to enhance the brain uptake of cationic dopamine by utilizing the large amino acid …

Simultaneous determination of levodopa, carbidopa and tryptophan using nanostructured electrochemical sensor based on novel hydroquinone and carbon …

M Mazloum-Ardakani, B Ganjipour, H Beitollahi… - Electrochimica …, 2011 - Elsevier
In the present paper, the use of a novel carbon paste electrode modified by 2, 2′-[1, 2-
ethanediylbis (nitriloethylidyne)]-bis-hydroquinone (EBNBH) and carbon nanotubes …

Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects: Prediction of Slow …

L Almeida, JF Rocha, A Falcão, P Nuno Palma… - Clinical …, 2013 - Springer
Abstract Background and Objectives Opicapone is a novel catechol-O-methyltransferase
(COMT) inhibitor. The purpose of this study was to evaluate the tolerability …

Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease

JJ Ferreira, JF Rocha, A Falcão… - European Journal of …, 2015 - Wiley Online Library
Background and purpose Opicapone (OPC) is a novel third generation catechol‐O‐
methyltransferase (COMT) inhibitor that enhances levodopa availability. This study …

Electrocatalytic oxidation and voltammetric determination of levodopa in the presence of carbidopa at the surface of a nanostructure based electrochemical sensor

M Mazloum-Ardakani, Z Taleat, A Khoshroo… - Biosensors and …, 2012 - Elsevier
In the present paper, the use of a carbon paste electrode modified by meso-tetrakis (3-
methylphenyl) cobalt porphyrin (CP) and TiO2 nanoparticles for the determination of …

Opicapone: a short lived and very long acting novel catechol‐O‐methyltransferase inhibitor following multiple dose administration in healthy subjects

JF Rocha, L Almeida, A Falcão… - British journal of …, 2013 - Wiley Online Library
Aims The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory
effect on erythrocyte soluble catechol‐O‐methyltransferase (S‐COMT) activity following …

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

JF Rocha, A Falcão, A Santos, R Pinto, N Lopes… - European journal of …, 2014 - Springer
Background and objectives Opicapone is a novel third generation catechol-O-
methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa …